Day: August 13, 2024

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML – – Commencement of $8 million grant award from CIRM for the clinical development of SENTI-202 – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2024 and provided a summary of recent corporate and pipeline highlights. “We have demonstrated important progress year to date, dosing patients in our Phase 1 clinical trial of SENTI-202 in AML and continuing to execute on our development pipeline priorities,” said Timothy Lu, MD, PhD, Chief...

– Continued Momentum in Revenue Growth Leads to Highest Second Quarter Revenue Performance Since 2009 – SEATTLE, Aug. 13, 2024 (GLOBE NEWSWIRE) — Jones Soda Co. (CSE: JSDA, OTCQB: JSDA) (“Jones Soda” or the “Company”), a beverage innovation company focused on developing, marketing and distributing cutting edge consumer drink and wellness products and a leading brand in the cannabis infused beverage category space, announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights vs. Year-Ago QuarterRevenue increased 49% to $7.2 million compared to $4.8 million. The second quarter of 2024 included approximately $1.2 million in revenue from the Company’s Mary Jones business compared to approximately $400,000 in the second quarter of 2023. Gross profit as a percentage of revenue...

DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024. The Company’s revenue for three months ended June 30, 2024, was $4.7 million versus $5.5 million for three months ended June 30, 2023, a decrease of 15%. Net loss was $0.8 million, or $0.14 per share, compared to a net loss of $0.7 million, or $0.13 per share, for the three months ended June 2024 and 2023, respectively. The Company’s revenue for six months ended June 30, 2024, was $10.1 million versus $11.4 million for six months ended June 30, 2023, a decrease of 12%. Net loss was $1.5 million, or $0.26 per share, compared to a net loss of $1.1 million, or $0.19 per share, for the six months ended June 2024...

LOUISVILLE, Ky., Aug. 13, 2024 (GLOBE NEWSWIRE) — LogicMark, Inc. (Nasdaq: LGMK), a provider of personal safety, personal emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial results for the quarter ended June 30, 2024. Summary:           Revenues were $2.3 million, up slightly compared with the prior year period. Gross margin in the second quarter of 2024 was 67%, compared with 69% for the second quarter of 2023. Overall operating expenses were $3.6 million, compared with $3.9 million for the prior year period. The cash balance on June 30, 2024 was $3.0 million. The Company’s intellectual property portfolio is expanding, with 14 patents filed since June 2021. This includes five provisional patents, three awarded patents, and the remaining...

Fourth quarter SaaS and support revenue of $85.0 million, up 25% year-over-year Fourth quarter total revenue of $114.4 million, up 21% year-over-year Cloud annual recurring revenue (ARR) of $296.7 million, up 33% year-over-yearPALO ALTO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Intapp, Inc. (NASDAQ: INTA), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms, announced financial results for its fourth quarter and fiscal year ended June 30, 2024. Intapp also provided its outlook for the first quarter and fiscal year 2025. “It has been a strong and exciting year for Intapp as we lead our clients to adopt and apply AI to the work of their professionals,” said John Hall, CEO of Intapp. “Our fiscal year 2024 results reflect the launch of our innovative new AI solutions,...

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers Abstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Cash balance of $97.5 million as of June 30, 2024 anticipated to fund key milestones through mid-2026REDWOOD CITY, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “During the second quarter, we continued to make significant progress across our two programs, BDC-3042 and BDC-4182, following our strategic pipeline prioritization in May,”...

PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highlights:Product sales increased 55% versus the comparable quarter in 2023. Product sales increased 82% versus the comparable six-month period in 2023. Product sales increased 48% from the previous trailing twelve-month period ended June 30, 2023.Management’s Discussion:“Our preliminary, unaudited product sales for the second quarter of 2024 were first reported on July 9, 2024,” commented Michael F. Brigham, President and CEO of ImmuCell....

MINNETONKA, Minn., Aug. 13, 2024 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos, announced financial results for the three and six months ending June 30, 2024. The 10-Q can be found @ http://www.sec.gov Second Quarter 2024 HighlightsThe Company installed two systems, our distributors expanded our system in new and current locations during the quarter.The Company has four customer contracts in backlog as of June 30, 2024. The company anticipates that the majority of these contracts will be installed in the next two quarters. As of the filing date of this report, the Company has signed one new contract.Financial Results System revenue for the quarter was $2M compared to $907K in 2023, an increase of...

CHICAGO, Aug. 13, 2024 (GLOBE NEWSWIRE) — Professional Diversity Network, Inc. (NASDAQ:IPDN), (“IPDN” or the “Company”), a global developer and operator of online and in-person networks that provides access to networking, training, educational and employment opportunities for diverse individuals, today announced its financial results for the quarter ended June 30, 2024. “The current recruiting market presents significant challenges. However, our recruitment services experienced a 3.2% revenue increase during the first two quarters of this year compared to the same period last year, demonstrating the effectiveness of our operational restructuring efforts. We remain committed to strategically targeting industries to establish ourselves as a leader in the diversity recruitment sector. RemoteMore has faced a slow demand for IT...